DGAP-News: novoGI Acquires an Exclusive License to Brand and Market a Next-Generation GI Endoscopic Video Processing Standalone Solution
(firmenpresse) - novoGI Inc.
31.12.2012 11:03
---------------------------------------------------------------------------
Expands Product Offerings for GI Surgeons and Market Applications
ATLANTA, 2012-12-31 11:03 CET (GLOBE NEWSWIRE) --
novoGI Inc. today announced that it has signed an agreement with Endopix Ltd.
for the exclusive worldwide right to market, distribute, sell and support a
novoGI-branded, standalone product based on next-generation video enhancement
software (Endoflag 200) in the fields of gastrointestinal (GI) diagnostic
endoscopy, GI surgical endoscopy, and GI laparoscopy. This innovative video
processing technology enhances visualization of image details of
tissue-primarily blood vessels, surface and patterns seen with existing
laparoscopes and video endoscopes.
Clinical evidence for the previous generation of this technology (Endoflag 100)
was presented at Digestive Disease Week (DDW) 2010. In a randomized,
prospective 124-patient international study1, the purely software-based image
filtering technique was used in real-time post-processing of endoscopic imaging
during ongoing colonoscopy. Diagnostic yield of post-processed images for
adenomas or cancers were compared to standard white light endoscopy.
The study's principal investigators (PIs) and co-authors, Ralf Kiesslich, MD,
Professor of Medicine and Head of Interdisciplinary Endoscopic Unit, University
Medical Center of Johannes Gutenberg University (JGU), Mainz, Germany and Zamir
Halpern, MD, Professor of Medicine and Head of Gastroenterology, Sackler
Faculty of Medicine, Tel Aviv University, Israel, concluded that the Endoflag
technology leads to a significantly higher detection rate of colorectal
neoplasias compared to standard white light endoscopy in a screening
population. In addition there was enhanced visualization of both vascular
structure and tissue morphology.
'We are excited to collaborate with novoGI and taking part in its expanding
platform, and are confident that this next generation technology will create
significant improvement in the diagnosis and treatment of GI diseases,'
commented Rami Guissin, Ph.D., Co-Founder and Chief Executive Officer of
Endopix.
novoGI President and Chief Executive Officer, Gavriel D. Meron added, 'We
believe that this video enhancement technology and its unmatched capabilities
will be a significant tool in the GI endoscopy suites and in clinical practice
for surgical endoscopy and laparoscopy, due to its potential to improve adenoma
detection rates, recognize vascular structure and perceive dysplasia in this
real-time application. We plan to introduce this new technology under the
novoGI brand during 2013.'
About novoGI
novoGI is focused on providing an expanding range of solutions for GI disease
management through a globally branded, high quality, market driven company. The
US headquarters are in Atlanta, Georgia; research, development and
manufacturing facilities in Netanya, Israel; and its European headquarters are
near Paris, France.
NOVOGI, the NOVOGI logo, the GI logo, and DEFINING THE FUTURE are trademarks
and/or registered trademarks of novoGI Inc.
About Endopix
Endopix Ltd., a privately held company, was founded in 2006 with the mission of
enhancing existing and future screening and surveillance endoscopes and
endoscopic procedures, benefiting both physicians and patients. Endopix is
engaged in the development and production of cost-effective, advanced
image/video processing and imaging technologies and solutions for enhanced
visualization and diagnostics in diverse endoscopic medical applications.
ENDOPIX, ENDOFLAG and the ENDOPIX logo are trademarks of Endopix Ltd.
For further information contact:
marcom(at)novoGI.com
www.novoGI.com
Reference
1. Kiesslich R, Doleschal A, Sar F, Hoffman A, Goetz M, Galle PR, Halpern Z.
Endoflag: a new software based filter technology significantly increases the
diagnostic yield of colorectal neoplasia during screening colonoscopy. A
prospective randomized controlled trial. [DDW website ePoster archive]
Presented at DDW 2010, New Orleans, LA, USA. ePoster S1526. Available at:
http://ddw.scientificposters.com/epsabstract.cfm?id=2
News Source: NASDAQ OMX
31.12.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: novoGI Inc.
Israel
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902064198
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
novogi-acquires-an-exclusive-license-to-brand-and-market-a-next
generation-gi-endoscopic-video-processing-standalone-solution
Unternehmensinformation / Kurzprofil:
Datum: 31.12.2012 - 11:03 Uhr
Sprache: Deutsch
News-ID 215925
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 336 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: novoGI Acquires an Exclusive License to Brand and Market a Next-Generation GI Endoscopic Video Processing Standalone Solution"
steht unter der journalistisch-redaktionellen Verantwortung von
novoGI Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
